Multibiomarker disease activity score an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis /

The multi-biomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in rheumatoid arthritis (RA). Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA.We performed a systematic literature search in five medical database...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Meznerics Fanni Adél
Kemény Lajos Vince
Gunther Emese Eszter
Bakó Eszter
Dembrovszky Fanni
Szabó Bence
Ascsillán Anna
Lutz Elmar
Csupor Dezső
Hegyi Péter
Bánvölgyi András
Nagy György
Dokumentumtípus: Cikk
Megjelent: 2023
Sorozat:RHEUMATOLOGY (UNITED KINGDOM) 62 No. 6
Tárgyszavak:
doi:10.1093/rheumatology/keac715

mtmt:33532353
Online Access:http://publicatio.bibl.u-szeged.hu/27000
Leíró adatok
Tartalmi kivonat:The multi-biomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in rheumatoid arthritis (RA). Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA.We performed a systematic literature search in five medical databases: MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, Scopus, and Web of Science, from inception to 13 October 2021. Original articles reporting on the performance of the MBDA score’s correlation with conventional disease activity measures, or the predictive and the discriminative value of the MBDA score for radiographic progression, therapy response, remission, and relapse were included.Our systematic search provided a total of 1190 records. After selection and citation searches, we identified 32 eligible studies. We recorded moderate correlations between MBDA score and conventional DAMs at baseline (COR = 0.45, CI: 0.28–0.59; I2 = 71.0% for DAS28 CRP and COR = 0.55, CI: 0.19–0.78; I2 = 0.0% for DAS28-ESR) and at follow-up (COR = 0.44, CI: 0.28–0.57; I2 = 70.0% for DAS28 CRP), and found that the odds of radiographic progression were significantly higher for patients with a high baseline MBDA score (>44) than for patients with a low baseline MBDA score (<30) (OR = 1.03, CI: 1.02–1.05; I2 = 10.0%).MBDA score might be used as an objective disease activity marker. In addition, it is also a reliable prognostic marker of radiographic progression.
Terjedelem/Fizikai jellemzők:2048-2059
ISSN:1462-0324